Safety and efficacy of a new medicinal drug BYON4228 in patients with non-Hodgkin lymphoma

  • Research type

    Research Study

  • Full title

    A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)



  • Contact name

    Evelyn Van den Tweel

  • Contact email

  • Sponsor organisation

    Byondis BV

  • Eudract number


  • Identifier


  • Research summary

    The purpose of this study is to evaluate the safety and activity of a new medicinal drug called BYON4228 in patients with Non-Hodgkin's Lymphoma. It is the first time that BYON4228 will be administered to humans. BYON4228 binds to a specific protein on immune cells and as a result it may improve the immune system and other drugs to attack the cancer. The safety and activity of BYON4228 will be evaluated when given alone and when given in combination with rituximab. Rituximab is an approved drug used to treat different kinds of cancers. In the first part of the study, the best dose of BYON4228 will be determined and in the second part of the study more patients will be treated with that dose.

  • REC name

    North East - York Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    20 Feb 2023

  • REC opinion

    Further Information Favourable Opinion